Charles River Laboratories (CRL) Tops Q3 EPS by 9c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $326.29 -7.27%
Financial Fact:
Net sales related to services: 292.85M
Today's EPS Names:
CIX, ARIS, COHR, More
Financial Fact:
Net sales related to services: 292.85M
Today's EPS Names:
CIX, ARIS, COHR, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.63, $0.09 better than the analyst estimate of $2.54. Revenue for the quarter came in at $989.2 million versus the consensus estimate of $974.65 million.
GUIDANCE:
Charles River Laboratories sees FY2022 EPS of $10.80-$10.95, versus the consensus of $10.80.
- Revenue growth, reported 10.0% – 11.0%
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viemed Healthcare, Inc. (VMD) Misses Q3 EPS by 2c; updates guidance
- Veracyte (VCYT) Tops Q3 EPS by 10c ; Offers Guidance
- ArcelorMittal (MT) Tops Q3 EPS by 36c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
